For many people with fatty liver disease, the fear is not just having fat in the liver, but having permanent scarring called cirrhosis. When this scarring is advanced but the liver is still working enough to be called compensated, the outlook can be serious. This research matters because it looks at the best available medicines to stop or reverse that scarring. The goal is to find a treatment that shrinks the scar tissue without causing the liver to fail or the disease to get worse.
The team looked at data from many different studies involving 3,266 patients. These patients all had biopsy-proven compensated MASH cirrhosis, which means they had confirmed scarring and inflammation but their liver was not yet failing. They compared several new drugs, including efruxifermin, semaglutide, and others, against a placebo which is an inactive pill used for comparison. The main question was which drug could push the scarring back by at least one stage without making the disease worse.
The results showed that efruxifermin was the only single drug that clearly beat the placebo at improving scarring. When looking at how well different treatments ranked overall, efruxifermin came in first. Other combinations, like semaglutide with two other drugs, also worked well to clear the fat and inflammation, but efruxifermin was the standout for fixing the scar tissue alone. The numbers used to measure this are complex, but the message is clear: this specific drug showed the strongest signal of benefit in this group.
Safety was a major part of this analysis. The study did not report specific side effects, serious events, or reasons why patients stopped taking the drugs. Because the safety details were not fully listed in this summary, doctors cannot yet say if these drugs are safe for everyone. Patients need to know that a lack of reported safety data does not mean a drug is risk-free, especially when the details are missing from the report.
It is important not to get too excited about this single study. It is a network analysis that combines many smaller trials, which is useful for ranking drugs, but it does not replace a large, dedicated trial for a specific patient. The study notes that these findings might help design future trials, but they do not mean patients should start taking these drugs immediately. Until more specific safety data and larger trials are done, the best advice is to talk with a doctor about the current standard of care.